British Biotech plc -"British Biotech"- Changes in Board Responsibilities.Business Editors/Biotechnology Writers OXFORD, U.K.--(BUSINESS WIRE)--May 31, 2001 British Biotech (LSE LSE - Language Sensitive Editor : BBG BBG Brooklyn Botanic Garden BBG Broadcasting Board of Governors BBG Bloomberg (financial company) BBG Bundesbeamtengesetz (German Law) BBG Bergbau-Berufsgenossenschaft (Germany) ; Nasdaq: BBIOY) today announced that Tim Edwards, an executive director of the company and currently Director of Business Development, has been promoted to Chief Business Officer. In his new role, Mr. Edwards' responsibilities are widened to include development of the company's strategy and review of the company's business and operations on a regular basis. In addition to his current executive responsibility for business development and the company's corporate project teams, Mr. Edwards is now responsible for Regulatory Affairs and Project Management. Commenting on the appointment, British Biotech's Chief Executive, Dr. Elliot Goldstein, said: "Tim has made an outstanding contribution to British Biotech's progress over the past two years. I wish him every success in his new role." This news release may contain forward-looking statements. Any such statements reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. These risks and uncertainties include, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, clinical research, the regulatory approval process, product commercialization and patent protection and the impact of competitive products and third party patents. The risks and uncertainties also include those detailed from time to time in the Company's periodic reports. About British Biotech British Biotech is a research and development stage biopharmaceutical company specializing in the development of new drugs to fight diseases for which there are limited treatment options. The company comprises two distinct businesses: a Product Portfolio of six drugs in development; and an Antibiotic Program with the potential for multiple product opportunities. Product Portfolio BB-10901 Collaboration with ImmunoGen Inc, USA; targeted at small cell lung cancer Lung Cancer, Small Cell Definition Small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description Lung cancer is divided into two main types: small cell and non-small cell. . E21R Collaboration with BresaGen Ltd, Australia; targeted at acute myeloid myeloid /my·eloid/ (mi´e-loid) 1. medullary; pertaining to, derived from, or resembling bone marrow or the spinal cord. 2. having the appearance of myelocytes, but not derived from bone marrow. leukaemia; other leukaemias; rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . BB-2827 Collaboration with Serono SA, Switzerland; targeted at rheumatoid arthritis, periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where . BB-76163 Collaboration with Serono; targeted at multiple sclerosis; cancer. BB-10153 Targeted at heart attack/stroke (thrombosis). Batimastat BiodivYsio(TM) stent Collaboration with Biocompatibles International plc, UK; targeted at vascular restenosis. Antibiotic Program British Biotech's research into metalloenzyme inhibitors as antibiotics is capable of yielding product opportunities in a number of fields. Polypeptide polypeptide: see peptide. deformylase inhibitors are in development for common respiratory infections such as community-acquired pneumonia community-acquired pneumonia Pneumonia caused by an infection currently present in the community; CAP is the most common cause of infectious death–US, and number 6 killer overall; of the 57% of CAPs in which a pathogen is identified, S pneumoniae . LpxC inhibitors are in pre-development as potential treatments for gram negative bacteria such as those causing urinary tract infections urinary tract infection (UTI), n infection in one or more of the structures that make up the urinary system. Occurs more often in women and is most commonly caused by bacteria. . Also under way are research programs into treatments for severe hospital-based infections and broad-spectrum antibiotics. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion